Veeba Foods ventures into child nutrition segment with V-Nourish
Category: #health  By Mateen Dalal  Date: 2019-05-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Veeba Foods ventures into child nutrition segment with V-Nourish

Condiments and sauce manufacturer Veeba Foods reportedly ventured into child nutrition segment with a new health beverage, V-Nourish.

According to sources close to the matter, V-Nourish is a scientifically designed nutritional supplement for kids aged above five years. It has been launched in a variety of flavors such as Strawberry, Kesar-Pista, Choco-Cookie and Badam. V-nourish is available in general and modern trade stores, across 100 cities in India.

Bollywood star Shah Rukh Khan has been roped in to promote the newly launched V-Nourish.

For the record, Founder of Veeba, Viraj Bahl and a team of Veeba research scientists are the innovators of V-Nourish. The nutritional supplement is claimed to contain over 40 Nutri-boosters, including micronutrients, high proteins, prebiotics and probiotics to support growth and over all development of children. V-Nourish vouches a unique product experience with the presence of nuts and real fruit chunks in every sip. The product is reportedly free of any synthetic colors, artificial flavors or added preservatives.

Viraj Bahl was quoted saying that the journey of V-Nourish started with the notion to provide best-in-class-nutrition to his children. While parents remain concerned with the child’s nutrition and subsequent growth, children are driven primarily by taste. After three years of research and development, the team has proudly announced V-Nourish which they expect to have the highest nutritional content in the category of child nutrition supplement, adds Viraj.

As a parent himself and a responsible food researcher and developer, he assures that making children finish their glass of milk will not be a trouble anymore.

The child health beverage market is estimated to be approximately Rs7000 crores, out of which premium nutrition segment is growing at a rate of 12% per year. Veeba is targeting to capture 5% of the market in the next year, said Viraj

As per credible source, V-nourish is being manufactured in a new facility at Keshwana, Rajasthan and the area spreads over 200,000 square feet of manufacturing space. Currently, the plant has around 300 workers employed in production.

Source credits: http://bwhotelier.businessworld.in/article/Veeba-Foods-Forays-into-Child-Nutrition-Segment/13-05-2019-170419/

https://www.thehindubusinessline.com/companies/veeba-foods-forays-into-child-nutrition-segment-sets-up-factory-in-rajasthan/article27108078.ece

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutic...

Ikea invests in India’s one-stop interior design platform Livspace
Ikea invests in India’s one-stop interior design platform Livspace
By Mateen Dalal

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in India’s ...

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
By Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailabil...